Free Trial

Passage Bio (PASG) Competitors

Passage Bio logo
$0.40 +0.02 (+6.26%)
As of 11:49 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

PASG vs. FBRX, CLLS, CLYM, CABA, MCRB, TCRX, VNRX, SRZN, EPIX, and PLRX

Should you be buying Passage Bio stock or one of its competitors? The main competitors of Passage Bio include Forte Biosciences (FBRX), Cellectis (CLLS), Climb Bio (CLYM), Cabaletta Bio (CABA), Seres Therapeutics (MCRB), TScan Therapeutics (TCRX), VolitionRx (VNRX), Surrozen (SRZN), ESSA Pharma (EPIX), and Pliant Therapeutics (PLRX). These companies are all part of the "pharmaceutical products" industry.

Passage Bio vs. Its Competitors

Passage Bio (NASDAQ:PASG) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

53.5% of Passage Bio shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 4.3% of Passage Bio shares are owned by company insiders. Comparatively, 5.9% of Forte Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Passage Bio has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 2.97, suggesting that its stock price is 197% more volatile than the S&P 500.

Passage Bio's return on equity of -93.59% beat Forte Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Passage BioN/A -93.59% -59.65%
Forte Biosciences N/A -149.15%-114.25%

Forte Biosciences is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Passage BioN/AN/A-$64.77M-$1.02-0.40
Forte BiosciencesN/AN/A-$35.48M-$16.29-0.80

Passage Bio presently has a consensus price target of $7.50, indicating a potential upside of 1,756.44%. Forte Biosciences has a consensus price target of $61.00, indicating a potential upside of 367.43%. Given Passage Bio's higher probable upside, analysts clearly believe Passage Bio is more favorable than Forte Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Passage Bio
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Forte Biosciences
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Passage Bio and Passage Bio both had 8 articles in the media. Forte Biosciences' average media sentiment score of 0.44 beat Passage Bio's score of -0.14 indicating that Forte Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Passage Bio
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Forte Biosciences
1 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Passage Bio beats Forte Biosciences on 6 of the 11 factors compared between the two stocks.

Get Passage Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for PASG and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PASG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PASG vs. The Competition

MetricPassage BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$25.11M$2.89B$5.49B$8.92B
Dividend YieldN/A2.69%5.38%4.12%
P/E Ratio-0.4021.3826.2019.83
Price / SalesN/A277.62404.03113.43
Price / CashN/A41.8936.4957.06
Price / Book0.417.347.985.35
Net Income-$64.77M-$55.05M$3.15B$248.34M
7 Day Performance23.93%1.69%1.48%2.40%
1 Month Performance-7.38%6.28%4.33%5.39%
1 Year Performance-59.58%4.67%35.36%19.53%

Passage Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PASG
Passage Bio
2.8744 of 5 stars
$0.40
+6.3%
$7.50
+1,756.4%
-57.0%$25.11MN/A-0.40130News Coverage
FBRX
Forte Biosciences
3.0587 of 5 stars
$12.93
+5.6%
$61.00
+371.8%
+56,859.7%$80.65MN/A0.005
CLLS
Cellectis
3.0072 of 5 stars
$1.53
+5.2%
$4.00
+162.3%
-19.9%$80.60M$49.22M-1.77290
CLYM
Climb Bio
3.7045 of 5 stars
$1.24
+5.1%
$9.00
+625.8%
N/A$79.74MN/A0.009News Coverage
Positive News
CABA
Cabaletta Bio
2.2833 of 5 stars
$1.52
-3.2%
$14.43
+849.2%
-80.0%$79.67MN/A0.0050Positive News
Gap Up
MCRB
Seres Therapeutics
3.6187 of 5 stars
$11.11
+22.1%
$73.67
+563.1%
-25.9%$79.46M$126.32M-2.42330Positive News
High Trading Volume
TCRX
TScan Therapeutics
2.9056 of 5 stars
$1.45
+3.6%
$7.80
+437.9%
-75.9%$79.23M$2.82M0.00100Gap Down
VNRX
VolitionRx
1.6355 of 5 stars
$0.76
-9.3%
$3.50
+360.5%
+23.9%$78.30M$1.31M-2.1180Gap Down
SRZN
Surrozen
2.9589 of 5 stars
$8.94
-0.9%
$38.50
+330.6%
-17.7%$77.24M$10.65M0.0080News Coverage
High Trading Volume
EPIX
ESSA Pharma
1.9735 of 5 stars
$1.70
-1.7%
$2.00
+17.6%
-66.2%$76.79MN/A-2.7050
PLRX
Pliant Therapeutics
4.2303 of 5 stars
$1.16
-7.2%
$13.31
+1,047.6%
-89.2%$76.73M$1.58M0.0090Gap Up
High Trading Volume

Related Companies and Tools


This page (NASDAQ:PASG) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners